Crossmark

Adis summary of research: Safety, tolerability and pharmacokinetics of aripiprazole 2-monthly formulation in patients with schizophrenia or bipolar I disorder

Crossref DOI link: https://doi.org/10.1007/s40267-024-01071-y

Published Online: 2024-06-27

Published Print: 2024-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Blair, Hannah A.
License Information

Text and Data Mining valid from 2024-05-01

Version of Record valid from 2024-05-01
More Information

Article History

Accepted: 14 May 2024

First Online: 27 June 2024

Declarations

:

: Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

: Not applicable.

Document is current

Any future updates will be listed below